The stock of Pasithea Therapeutics Corp (NASDAQ: KTTA) has increased by 46.15 when compared to last closing price of 2.08.Despite this, the company has seen a gain of 22.58% in its stock price over the last five trading days. globenewswire.com reported 2025-02-05 that Pasithea’s PAS-004 Phase 1 trial advances to 22mg dose with no DLTs or rash, reinforcing its safety profile as a next-gen MEK inhibitor for NF1 and cancer.
Is It Worth Investing in Pasithea Therapeutics Corp (NASDAQ: KTTA) Right Now?
The 36-month beta value for KTTA is at 0.65. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KTTA is 1.02M, and currently, shorts hold a 1.00% of that float. The average trading volume for KTTA on February 05, 2025 was 45.34K shares.
KTTA’s Market Performance
KTTA’s stock has seen a 22.58% increase for the week, with a -2.56% drop in the past month and a -20.00% fall in the past quarter. The volatility ratio for the week is 8.79%, and the volatility levels for the past 30 days are at 7.85% for Pasithea Therapeutics Corp The simple moving average for the past 20 days is 21.58% for KTTA’s stock, with a -33.26% simple moving average for the past 200 days.
KTTA Trading at 11.80% from the 50-Day Moving Average
After a stumble in the market that brought KTTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.14% of loss for the given period.
Volatility was left at 7.85%, however, over the last 30 days, the volatility rate increased by 8.79%, as shares sank -2.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.64% lower at present.
During the last 5 trading sessions, KTTA rose by +21.37%, which changed the moving average for the period of 200-days by -63.50% in comparison to the 20-day moving average, which settled at $2.50. In addition, Pasithea Therapeutics Corp saw -3.49% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KTTA
Current profitability levels for the company are sitting at:
- -16.53 for the present operating margin
- 0.5 for the gross margin
The net margin for Pasithea Therapeutics Corp stands at -16.16. The total capital return value is set at -0.9. Equity return is now at value -68.24, with -63.93 for asset returns.
Currently, EBITDA for the company is -15.33 million with net debt to EBITDA at 0.6. When we switch over and look at the enterprise to sales, we see a ratio of -5.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.81.
Conclusion
In conclusion, Pasithea Therapeutics Corp (KTTA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
